ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT00394082. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of Weekly Administration of ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in combination with bevacizumab. The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients with previously untreated advanced/metastatic breast cancer.
Study identification
- NCT ID
- NCT00394082
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 1, 2006 (Actual)
- Primary completion
- Sep 1, 2009 (Actual)
- Completion
- Feb 1, 2011 (Actual)
- Last update posted
- Nov 25, 2019
2006 – 2011
United States locations
- U.S. sites
- 20
- U.S. states
- 9
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Melbourne | Florida | 32901 | — |
| Not listed | Ocoee | Florida | 34761 | — |
| Not listed | Niles | Illinois | 60714 | — |
| Not listed | Terre Haute | Indiana | 47802 | — |
| Not listed | Columbia | Maryland | 21044 | — |
| Not listed | Westminister | Maryland | 21157 | — |
| Not listed | Saint Joseph | Missouri | 64507 | — |
| Not listed | Rochester | New York | 14623 | — |
| Not listed | Bedford | Texas | 76022 | — |
| Not listed | Dallas | Texas | 75246 | — |
| Not listed | El Paso | Texas | 79915 | — |
| Not listed | Odessa | Texas | 79761 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Tyler | Texas | 75702 | — |
| Not listed | Fairfax | Virginia | 22031 | — |
| Not listed | Norfolk | Virginia | 23502 | — |
| Not listed | Salem | Virginia | 24153 | — |
| Not listed | Burien | Washington | 98166 | — |
| Not listed | Edmonds | Washington | 98026 | — |
| Not listed | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00394082, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 25, 2019 · Synced Oct 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00394082 live on ClinicalTrials.gov.